Scholarlink

Background <p>Ovarian cancer (OC) remains among the deadliest cancers in women worldwide. Anoikis, a critical process that prevents the establishment of detached cells in non-native sites, is closely associated with cancer cell aggressiveness and poor patient outcomes. Despite its significance, research into the prognostic impact of anoikis-related genes (ARGs) in OC remains scant.</p> Methods <p>Single-cell RNA sequencing (scRNA-seq) was adopted to analyze anoikis activity. We used 41 ARGs across distinct cell types for this analysis. The genomic and clinicopathological data was sourced from GSE26712 project (training cohort) and TCGA-OV project (independent validation set), respectively. Cox regression and the least absolute shrinkage and selection operator (LASSO) technique were utilized to develop an anoikis-related risk score (ANRS) for prognosis evaluation. Additionally, the correlation between ANRS and tumor microenvironment (TME) characteristics was explored. Functional experiments were conducted to elucidate the molecular role of the key gene AP1S2 in OC.</p> Results <p>Survival analyses in both cohorts categorized OC patients into two groups based on the median ANRS. The high-ANRS category exhibited evidently worse survival outcomes. Our findings highlighted a strong link between ARGs and TME characteristics, particularly the stromal components, at both bulk and single-cell transcriptomic levels. This underscores the complex interplay between cancer progression and the tumor-promoting stroma. Additionally, AP1S2 knockdown markedly reduced the proliferative and aggressive capabilities of OC cells.</p> Conclusion <p>The ANRS-derived prognostic tool offers substantial promise for advancing our understanding of OC progression and assisting gynecologists in developing effective treatment strategies for women suffering from this malignancy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of anoikis-related tumor microenvironment characteristics and prognostic signature in ovarian cancer at bulk and single-cell levels

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Zhenye Tang,
  • Chenfei Zhou,
  • Yinyin Xu,
  • Zhizai Chen,
  • Shuting Huang,
  • Jing Chen,
  • Ping Jin,
  • Jiemei Hu,
  • Shanyang He

摘要

Background

Ovarian cancer (OC) remains among the deadliest cancers in women worldwide. Anoikis, a critical process that prevents the establishment of detached cells in non-native sites, is closely associated with cancer cell aggressiveness and poor patient outcomes. Despite its significance, research into the prognostic impact of anoikis-related genes (ARGs) in OC remains scant.

Methods

Single-cell RNA sequencing (scRNA-seq) was adopted to analyze anoikis activity. We used 41 ARGs across distinct cell types for this analysis. The genomic and clinicopathological data was sourced from GSE26712 project (training cohort) and TCGA-OV project (independent validation set), respectively. Cox regression and the least absolute shrinkage and selection operator (LASSO) technique were utilized to develop an anoikis-related risk score (ANRS) for prognosis evaluation. Additionally, the correlation between ANRS and tumor microenvironment (TME) characteristics was explored. Functional experiments were conducted to elucidate the molecular role of the key gene AP1S2 in OC.

Results

Survival analyses in both cohorts categorized OC patients into two groups based on the median ANRS. The high-ANRS category exhibited evidently worse survival outcomes. Our findings highlighted a strong link between ARGs and TME characteristics, particularly the stromal components, at both bulk and single-cell transcriptomic levels. This underscores the complex interplay between cancer progression and the tumor-promoting stroma. Additionally, AP1S2 knockdown markedly reduced the proliferative and aggressive capabilities of OC cells.

Conclusion

The ANRS-derived prognostic tool offers substantial promise for advancing our understanding of OC progression and assisting gynecologists in developing effective treatment strategies for women suffering from this malignancy.